Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug Administration (FDA) to study its NK510 in advanced solid tumors, following clinical approval in China last month. This development marks a significant step forward for the company’s base-edited universal NK cell therapy.
NK510: A Leap Forward in Cell Therapy
The NK510 cell injection represents a major advancement in the field of cell therapy. Utilizing Base Therapeutics’ proprietary AccuBase technology, which offers off-target-free base editing, NK510 has achieved over 90% editing efficiency in NK cells. This high level of precision allows for the accurate modification of key genes, potentially enhancing the cells’ anti-tumor capabilities.
Strong Anti-Tumor Potential of NK510
The product has shown strong anti-tumor ability in a range of trials, including in vitro, in vivo, and clinical studies. These positive results have supported the decision to advance NK510 into further clinical studies, with the aim of improving outcomes for patients with advanced solid tumors.-Fineline Info & Tech
Leave a Reply